GLENMARK PHARMACEUTICALS Q3 FY24 Results

GLENMARK PHARMACEUTICALS has released its financial results for the Q3 quarter of Financial Year 23-2024. Here's a comprehensive breakdown of the company's performance:

Revenue Analysis

• Current Quarter Revenue: Rs. 2,506.70 Cr
• Quarter-on-Quarter (QoQ) Change: -21.85% (Previous Quarter: Rs. 3,207.38 Cr )
• Year-on-Year (YoY) Change: -27.63% (Same Quarter Last Year: Rs. 3,463.86 Cr )

Profitability Metrics

• Net Profit: Rs. -330.82 Cr
• QoQ Profit Change: 420.53% (Previous Quarter: Rs. -63.55 Cr )
• YoY Profit Change: -213.78% (Same Quarter Last Year: Rs. 290.76 Cr )

Shareholder Returns

• Earnings Per Share (EPS): Rs. -12.45
• QoQ EPS Change: 329.31% (Previous Quarter: Rs. -2.90)
• YoY EPS Change: -228.88% (Same Quarter Last Year: Rs. 9.66)

Performance Summary

Mixed

GLENMARK PHARMACEUTICALS had a complex financial situation. Different parts of the business are performing differently, showing a changing market.

This analysis provides a snapshot of GLENMARK PHARMACEUTICALS's financial performance. Investors and analysts should consider these results in the context of broader market trends and the company's long-term strategy.